Simona Colla, PhD

Peer-Reviewed Articles

1. Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Rep Med 5(6):101585, 2024. e-Pub 2024. PMID: 38781960.
2. Marchesini M, Gherli A, Simoncini E, Tor LMD, Montanaro A, Thongon N, Vento F, Liverani C, Cerretani E, D'Antuono A, Pagliaro L, Zamponi R, Spadazzi C, Follini E, Cambò B, Giaimo M, Falco A, Sammarelli G, Todaro G, Bonomini S, Adami V, Piazza S, Corbo C, Lorusso B, Mezzasoma F, Lagrasta CAM, Martelli MP, La Starza R, Cuneo A, Aversa F, Mecucci C, Quaini F, Colla S, Roti G. Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML. Nat Commun 15(1):4739, 2024. e-Pub 2024. PMID: 38834613.
3. Patel B, Zhou Y, Babcock RL, Ma F, Zal MA, Kumar D, Medik YB, Kahn LM, Pineda JE, Park EM, Schneider SM, Tang X, Raso MG, Jeter CR, Zal T, Clise-Dwyer K, Keyomarsi K, Giancotti FG, Colla S, Watowich SS. STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response. Leukemia 38(5):1143-1155, 2024. e-Pub 2024. PMID: 38467768.
4. Rodriguez-Sevilla JJ, Ganan-Gomez I, Ma F, Chien K, Del Rey M, Loghavi S, Montalban-Bravo G, Adema V, Wildeman B, Kanagal-Shamanna R, Bazinet A, Chifotides HT, Thongon N, Calvo X, Hernández-Rivas JM, Díez-Campelo M, Garcia-Manero G, Colla S. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. Nat Commun 15(1):2428, 2024. e-Pub 2024. PMID: 38499526.
5. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Combination of oral decitabine/cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: results of a single-centre, phase 1-2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
6. Patel B, Zhou Y, Babcock RL, Ma F, Zal MA, Kumar D, Medik YB, Kahn LM, Pineda JE, Park EM, Tang X, Raso MG, Zal T, Clise-Dwyer K, Giancotti FG, Colla S, Watowich SS. STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity. Leukemia, 2024. e-Pub 2024. PMID: 36798265.
7. Thongon N, Ma F, Baran N, Lockyer P, Liu J, Jackson C, Rose A, Furudate K, Wildeman B, Marchesini M, Marchica V, Storti P, Todaro G, Ganan-Gomez I, Adema V, Rodriguez-Sevilla JJ, Qing Y, Ha MJ, Fonseca R, Stein C, Class C, Tan L, Attanasio S, Garcia-Manero G, Giuliani N, Berrios Nolasco D, Santoni A, Cerchione C, Bueso-Ramos C, Konopleva M, Lorenzi P, Takahashi K, Manasanch E, Sammarelli G, Kanagal-Shamanna R, Viale A, Chesi M, Colla S. Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma. Nature Commun. e-Pub 2024. PMID: 38331987.
8. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108(10):2626-2638, 2023. e-Pub 2023. PMID: 37078252.
9. Adema V, Ganan-Gomez I, Ma F, Rodriguez-Sevilla JJ, Chien K, Yang H, Thongon N, Kanagal-Shamanna R, Loghavi S, Montalban-Bravo G, Hammond D, Gu Y, Tan R, Tan L, Lorenzi P, Al-Atrash G, Clise-Dwyer K, Bejar R, Pellegrini M, Garcia-Manero G, Colla S. IL-1β-mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes. bioRxiv, 2023. e-Pub 2023. PMID: 37808770.
10. Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez IG, Rodriguez-Sevilla JJ, Adema V, Wildeman B, Lockyer P, Kim YJ, Tanaka T, Darbaniyan F, Pancholy S, Zhang G, Al-Atrash G, Dwyer K, Takahashi K, Garcia-Manero G, Kantarjian H, Colla S. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia. bioRxiv, 2023. e-Pub 2023. PMID: 37066354.
11. Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discov 3(6):554-567, 2022. e-Pub 2022. PMID: 35926182.
12. Li Z, Wang Y, Ganan-Gomez I, Colla S, Do KA. A machine learning-based method for automatically identifying novel cells in annotating single-cell RNA-seq data. Bioinformatics 38(21):4885-4892, 2022. e-Pub 2022. PMID: 36083008.
13. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
14. Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G. Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia 36(8):2097-2107, 2022. e-Pub 2022. PMID: 35697791.
15. Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
16. Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun 12(1):6850, 2021. e-Pub 2021. PMID: 34824242.
17. Chakravarti D, Lee R, Multani AS, Santoni A, Keith Z, Hsu WH, Chang K, Reyes L, Rashid A, Wu CJ, Li J, Zhang J, Shim HS, Chandra K, Deng P, Spring DJ, Nielsen OH, Riis LB, Mayigegowda KK, Blutt SE, Zhang J, Younes M, DuPont A, Thirumurthi S, Vilar E, Estes MK, Colla S, Shroyer NF, DePinho RA. Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proc Natl Acad Sci U S A 118(29), 2021. e-Pub 2021. PMID: 34253611.
18. Nofrini V, Matteucci C, Pellanera F, Gorello P, Di Giacomo D, Lema Fernandez AG, Nardelli C, Iannotti T, Brandimarte L, Arniani S, Moretti M, Gili A, Roti G, Di Battista V, Colla S, Mecucci C. Activating somatic and germline TERT promoter variants in myeloid malignancies. Leukemia 35(1):274-278, 2021. e-Pub 2021. PMID: 32366939.
19. Frenquelli M, Caridi N, Antonini E, Storti F, Viganò V, Gaviraghi M, Occhionorelli M, Bianchessi S, Bongiovanni L, Spinelli A, Marcatti M, Belloni D, Ferrero E, Karki S, Brambilla P, Martinelli-Boneschi F, Colla S, Ponzoni M, DePinho RA, Tonon G. The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. Leukemia 34(1):257-270, 2020. e-Pub 2020. PMID: 31148590.
20. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. e-Pub 2019. PMID: 30902805.
21. Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero-G. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv 2(19):2491-2504, 2018. e-Pub 2018. PMID: 30275007.
22. Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
23. Ong DST, Hu B, Ho YW, Sauvé CG, Bristow CA, Wang Q, Multani AS, Chen P, Nezi L, Jiang S, Gorman CE, Monasterio MM, Koul D, Marchesini M, Colla S, Jin EJ, Sulman EP, Spring DJ, Yung WA, Verhaak RGW, Chin L, Wang YA, DePinho RA. PAF promotes stemness and radioresistance of glioma stem cells. Proc Natl Acad Sci U S A 114(43):E9086-E9095, 2017. e-Pub 2017. PMID: 29073105.
24. Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Cancer Cell 32(1):88-100.e6, 2017. e-Pub 2017. PMID: 28669490.
25. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
26. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
27. Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18(1):100-111, 2017. e-Pub 2017. PMID: 27923552.
28. Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl:S67-73, 2016. e-Pub 2016. PMID: 27521329.
29. Cabrero M, Wei Y, Yang H, Ganan-Gomez I, Bohannan Z, Colla S, Marchesini M, Bravo GM, Takahashi K, Bueso-Ramos C, Garcia-Manero G. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res 44:1-7, 2016. e-Pub 2016. PMID: 26970171.
30. Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y. Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. Br J Haematol 173(1):161-5, 2016. e-Pub 2016. PMID: 26105212.
31. Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, Corson L, Feala J, Fekkes P, Ichikawa K, Keaney GF, Lee L, Kumar P, Kunii K, MacKenzie C, Matijevic M, Mizui Y, Myint K, Park ES, Puyang X, Selvaraj A, Thomas MP, Tsai J, Wang JY, Warmuth M, Yang H, Zhu P, Garcia-Manero G, Furman RR, Yu L, Smith PG, Buonamici S. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. Cell Rep 13(5):1033-45, 2015. e-Pub 2015. PMID: 26565915.
32. Colla S, Ong DS, Ogoti Y, Marchesini M, Mistry NA, Clise-Dwyer K, Ang SA, Storti P, Viale A, Giuliani N, Ruisaard K, Ganan Gomez I, Bristow CA, Estecio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Multani AS, Jiang S, Hua S, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D'Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LJ, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DePinho RA. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27(5):644-57, 2015. e-Pub 2015. PMID: 25965571.
33. Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res 75(6):1091-101, 2015. e-Pub 2015. PMID: 25736685.
34. Yang H, Maddipoti S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of class I and II histone deacetylase gene expression in human leukemia. Leuk Lymphoma 56(12):3426-33, 2015. e-Pub 2015. PMID: 25944469.
35. Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J 5:e333, 2015. e-Pub 2015. PMID: 26230957.
36. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-32, 2014. e-Pub 2014. PMID: 25119024.
37. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, David Roodman G, Giuliani N. Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 27(8):1697-706, 2013. e-Pub 2013. PMID: 23344526.
38. Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F, Giuliani N. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia 27(2):451-63, 2013. e-Pub 2013. PMID: 22781592.
39. Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov 2(8):736-49, 2012. e-Pub 2012. PMID: 22750848.
40. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337-42, 2012. e-Pub 2012. PMID: 22895339.
41. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, Perry SR, Jiang S, Malinn B, Protopopov A, Colla S, Xiao Y, Hezel AF, Bardeesy N, Turley SJ, Wang YA, Chin L, Thayer SP, DePinho RA. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov 1(2):158-69, 2011. e-Pub 2011. PMID: 21984975.
42. Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia 25(3):527-37, 2011. e-Pub 2011. PMID: 21183939.
43. Sahin E, Colla S, Liesa M, Moslehi J, Müller FL, Guo M, Cooper M, Kotton D, Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin L, DePinho RA. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470(7334):359-65, 2011. e-Pub 2011. PMID: 21307849.
44. Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V, Giuliani N. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol 39(1):55-65, 2011. e-Pub 2011. PMID: 20977926.
45. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, Fletcher-Sananikone E, Colla S, Wang YA, Chin L, Depinho RA. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468(7324):701-4, 2010. e-Pub 2010. PMID: 21124456.
46. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24(11):1967-70, 2010. e-Pub 2010. PMID: 20811474.
47. Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia 24(7):1368-70, 2010. e-Pub 2010. PMID: 20485369.
48. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 38(2):141-53, 2010. e-Pub 2010. PMID: 19963035.
49. Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini C, Codeluppi K, Facchini A, Rizzoli V. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res 68(16):6840-50, 2008. e-Pub 2008. PMID: 18703490.
50. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, Taverniti G, Di Carlo E, Cutrona G, Perfetti V, Rizzoli V, Ribatti D, Pistoia V. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 112(3):750-9, 2008. e-Pub 2008. PMID: 18474725.
51. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A, Greco A, Mangoni M, Bonati A, Rizzoli V, Giuliani N. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110(13):4464-75, 2007. e-Pub 2007. PMID: 17848618.
52. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 109(11):4995-5001, 2007. e-Pub 2007. PMID: 17303695.
53. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109(10):4470-7, 2007. e-Pub 2007. PMID: 17255354.
54. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276-84, 2007. e-Pub 2007. PMID: 17105813.
55. Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M, Rizzoli V. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91(11):1489-97, 2006. e-Pub 2006. PMID: 17082008.
56. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood 108(6):2020-8, 2006. e-Pub 2006. PMID: 16728703.
57. Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, Mancini C, Pedrazzoni M, Crugnola M, Rizzoli V, Giuliani N. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 19(12):2166-76, 2005. e-Pub 2005. PMID: 16208410.
58. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Haematologica 90(2):275-8, 2005. e-Pub 2005. PMID: 15710592.
59. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S Rizzoli V, Roodman GD, Giuliani N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106(4):1407-14, 2005. e-Pub 2005. PMID: 15878977.
60. Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica 89(9):1118-23, 2004. e-Pub 2004. PMID: 15377473.
61. Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 18(3):628-35, 2004. e-Pub 2004. PMID: 14737074.
62. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102(2):638-45, 2003. e-Pub 2003. PMID: 12649156.
63. Giuliani N, Caramatti C, Roti G, Geata A, Colla S, Bonomini S, Hojden M, La Monica S, Sammarelli G, Lazzaretti M, Craviotto L, Mangoni L, Rizzoli V. Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol 21(9):1887-8, 2003. e-Pub 2003. PMID: 12721268.
64. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M, Sammarelli G, Barillè S, Bataille R, Rizzoli V. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100(13):4615-21, 2002. e-Pub 2002. PMID: 12393684.
65. Cilloni D, Carlo-Stella C, Falzetti F, Sammarelli G, Regazzi E, Colla S, Rizzoli V, Aversa F, Martelli MF, Tabilio A. Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation. Blood 96(10):3637-43, 2000. e-Pub 2000. PMID: 11071665.
66. Fogli M, Carlo-Stella C, Curti A, Ratta M, Tazzari PL, Ragazzi E, Colla S, Santucci AM, Tura S, Lemoli RM. Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. Exp Hematol 28(7):775-83, 2000. e-Pub 2000. PMID: 10907639.
67. Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 93(11):3973-82, 1999. e-Pub 1999. PMID: 10339507.

Invited Articles

1. Rodriguez-Sevilla JJ, Colla S. T cell dysfunctions in myelodysplastic syndromes. Blood 143(14):1329-1343, 2024. e-Pub 2024. PMID: 38237139.
2. Rodriguez-Sevilla JJ, Adema V, Garcia-Manero G, Colla S. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Rep Med 4(2):100940, 2023. e-Pub 2023. PMID: 36787738.
3. Ganan-Gomez I, Clise-Dwyer K, Colla S. Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes. STAR Protoc 3(4):101764, 2022. e-Pub 2022. PMID: 36240061.
4. Fiorini E, Santoni A, Colla S. Dysfunctional telomeres and hematological disorders. Differentiation 100:1-11, 2018. e-Pub 2018. PMID: 29331736.
5. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7):1458-69, 2015. e-Pub 2015. PMID: 25761935.
6. Giuliani N, Colla S, Morandi F, Rizzoli V. Angiopoietin-1 and myeloma-induced angiogenesis. Leuk Lymphoma 46(1):29-33, 2005. e-Pub 2005. PMID: 15621778.
7. Giuliani N, Colla S, Rizzoli V. Update on the pathogenesis of osteolysis in multiple myeloma patients. Acta Biomed 75(3):143-52, 2004. e-Pub 2004. PMID: 15796087.
8. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 32(8):685-91, 2004. e-Pub 2004. PMID: 15308315.
9. Colla S, Sammarelli G, Crugnola M, Ascani S, Sabbatini E, Bonomini S, Hojden M, Craviotto L, De Celis I, Morandi F, Caramatti C, Rizzoli V, Giuliani N. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. Eur J Haematol 72(5):361-5, 2004. e-Pub 2004. PMID: 15059073.
10. Giuliani N, Colla S, Rizzoli V. Angiogenic switch in multiple myeloma. Hematology 9(5-6):377-81, 2004. e-Pub 2004. PMID: 15763977.

Editorials

1. Rodriguez-Sevilla JJ, Colla S. A Roadmap of Relapse in MDS after Allo-HSCT. Blood 143(11):941-943, 2024. PMID: 38483410.
2. Adema V, Colla S. EZH2 Inhibitors: The Unpacking Revolution. Cancer Res 82(3):359-361, 2022. PMID: 35110396.
3. Marchesini M, Fiorini E, Colla S. RNA processing: a new player of genomic instability in multiple myeloma. Oncoscience 4(7-8):73-74, 2017. PMID: 28966938.

Abstracts

1. Rodriguez-Sevilla JJ, Liu Y, Ganan-Gomez I, Adema V, Chien K, Montalban-Bravo G, Kanagal-Shamanna R, Thongon N, Loghavi S, Garcia-Manero G, Wang L, Simona Colla S. Single cell T-cell landscape in myelodysplastic syndrome during venetoclax therapy. EHA, 2024. e-Pub 2024.
2. Montalban-Bravo G, Thongon N, Rodriguez-Sevilla J, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S. Targeting Mcl1-driven anti-apoptotic pathways overcome blast progression after hypomethylating agent resistance in chronic myelomonocytic leukemia. EHA, 2024. e-Pub 2024.
3. Rodriguez-Sevilla JJ, Ganan-Gomez I, Adema V, Garcia-Manero G, Colla| S. Myelodysplastic Syndrome Hematopoietic Stem Cells’ Plasticity Drives Venetoclax Therapy Escape. Keystone Symphosia, Hematopoiesis, 2024. e-Pub 2024.
4. Adema V, Colla S. Targeting the EIF2AK1 Signaling Pathway to Overcome Anemia in SF3B1-mutant Myelodysplastic Syndromes with Ringed Sideroblasts. Erythropoiesis: Development, Function and Disease, 2023. e-Pub 2023.
5. Thongon N, Colla S. Targeting DNA2 overcomes metabolic reprogramming in 1q21 myeloma. AACR Basic and Translational Conference, 2023. e-Pub 2023.
6. Gutierrez-Rodrigues F, Thongon N, Williams C, Colla S, Young N, Bertuch A. Blood Count Recovery and Telomere Elongation in a TINF2 Patient Under Treatment with a Gonadotropin-Releasing Hormone (GnRH) Agonist. Blood, 2023. e-Pub 2023.
7. Ganan-Gomez I, Kumar B, Rodriguez Sevilla JJ, Ma F, Kim YJ, Chien KS, Nelson K, Yang H, Tan R, Li Z, Tanaka T, Uryu H, Kanagal-Shamanna R, Loghavi S, Alatrash G, Bejar R, Rezvani K, Takahashi K, Garcia-Manero G, Daher M, Colla S. Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones. Blood, 2023. e-Pub 2023.
8. Rodriguez Sevilla JJ, Ganan-Gomez I, Feiyang, Ma, Chien K, Montalban-Bravo G, Kanagal-Shamanna R, Loghavi S, Adema V, Thongon N, Bazinet A, Garcia-Manero G, Colla AS. Myelodysplastic Syndrome Hematopoietic Stem Cells Can Undergo Differentiation Trajectory Rewiring to Escape Venetoclax Vulnerability. Blood, 2023. e-Pub 2023.
9. Thongon N, Colla S. Targeting DNA2 overcomes metabolic reprogramming in 1q21 myeloma. EHA, 2023. e-Pub 2023.
10. Garcia-Manero G, Adema V, Urrutia S, Ma F, Yang H, Ganan-Gomez I, Borthakur G, Takahashi K, Short N, Issa GC, Chien KS, Montalban-Bravo G, Joseph J, Colla AS. Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial. Blood, 2022. e-Pub 2022.
11. Marchesini M, Gherli A, Simoncini E, Montanaro A, Thongon N, Pagliari L, Vento F, Dalla Tor LM, Liverani C, Zamponi R, Follini E, Cambò B, MD, Lorusso B, Starza RL, Cuneo A, Mecucci C, Quaini F, Colla S, Roti AG. Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML. Blood, 2022. e-Pub 2022.
12. Uryu H, Saeki K, Nangalia J, Spencer M, Zhao L, Hsu JI, Bueso-Ramos CE, Shujuan, Yang H, Kantarjian H, DiNardo CD, Daver N, Colla S, Shpall EJ, Garcia-Manero G, Haeno H, Futreal A, Takahashi AK. Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis. Blood, 2022. e-Pub 2022.
13. Montalban-Bravo G, Ma F, Ganan-Gomez I, Kanagal-Shamana R, Adema V, Thongon N, Yang H, Soltysiak KA, Bueso-Ramos C, Kantarjian H, Garcia-Manero G, Colla AS. Determinant of Disease Progression after HMA failure in Ras mutant CMML at the single-cell levels. EHA, 2022. e-Pub 2022.
14. Groarke EM, Gutierrez-Rodrigues F, Ma X, Patel BA, Spitofsky N, Browne PV, Chien KS, Wu CO, DiNardo CD, Colla S, Calado RT, Young NS. U2AF1 and Other Splicing Factor Gene Mutations in Telomere Biology Disorders Are Associated with Hematologic Neoplasia and Worse Overall Survival. Blood, 2021. e-Pub 2021.
15. Wei Y, Zheng H, Lockyer P, Bao N, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Do K, Colla S, Chien KS, Montalban-Bravo G, Daver N, Garcia-Manero G. Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood, 2021. e-Pub 2021.
16. Thongon N, Santoni A, Lui J, Baran N, Ma F, Jackson C, Lockyer P, Ganan-Gomez I, Jin Ha YQM, Marchesini M, Class C, Pellegrini M, LinTan, Lorenzi P, Konopleva M, Colla AS. Targeting DNA2 overcomes myeloma cells’ metabolic reprogramming in response to DNA damage. International Myeloma Workshop 2021, 2021. e-Pub 2021.
17. Adema V, Ma F, Kanagal-Shamanna R, Yang H, Thongon N, Peslak SA, Gañán-Gómez I, Lockyer P, Wang F, Acha P, Sole F, Montalban-Bravo G, Maciejewski JP, Visconte V, Bueso-Ramos C, Pellegrini M, Carew JS, Dwyer K, Blobel GA, Garcia-Manero G, Colla AS. Single-cell analysis of SF3B1 mutant Myelodysplastic syndromes with ringed sideroblasts. MDS Foundation, 2021. e-Pub 2021.
18. Thongon N, Santoni A, Liu J, Baran N, Ma F, Jackson C, Lockyer P, Ganan-Gomez I, Adema V, Rose A, Marchesini M, Qing Y, Ha MJ, Class C, Pellegrini M, Tan L, Lorenzi P, Konopleva M, Colla S. Targeting DNA2 Overcomes Myeloma Cells' Metabolic Reprogramming in Response to DNA Damage. Blood, 2021. e-Pub 2021.
19. Ganan-Gomez I, Chien KS, Ma F, Yang H, Tan L, Lorenzi P, Garcia-Manero G, Colla AS. The Transcriptional and Epigenetic Reprogramming of Aged Hematopoietic Stem Cells Drives Myeloid Rewiring in Clonal Hematopoiesis-Associated Cytopenias. Blood, 2021. e-Pub 2021.
20. Montalban-Bravo G, Ma F, Ganan-Gomez I, Kanagal-Shamanna R, Adema V, Wei Y, Chien KS, Thongon N, Yang H, Bueso-Ramos CE, Kantarjian H, Garcia-Manero G, Colla AS. Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia. Blood, 2021. e-Pub 2021.
21. Gutierrez-Rodrigues F, Groarke EM, Clé DV, Patel BA, Donaires FS, Spitofsky N, Alemu L, Santana BA, Kajigaya S, Colla S, De Oliveira MM, S Bonfim CM, Calado RT, Young NS. Clonal Hematopoiesis in Telomere Biology Disorders Associates with the Underlying Germline Defect and Somatic Mutations in POT1, PPM1D, and TERT promoter. Blood, 2021. e-Pub 2021.
22. Kanagal-Shamanna R, Adema V, Ma F, Santoni A, Yang H, Ganan-Gomez I, Thongon N, Montalban-Bravo G, Pellegrini M, Bueso-Ramos CE, Garcia-Manero G, Colla S. SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level. Blood, 2020. e-Pub 2020.
23. Thongon N, Colla S. ILF2 antisense oligonucleotide therapy and CRISPR/Cas9-based screening for DNA repair effectors identify synthetic lethal approaches to enhancing myeloma cells’ sensitivity to DNA damage. International Myeloma Workshop 2019, 2019. e-Pub 2019.
24. Santoni A, Ma F, Fiorini E, Thongon N, Jackson C, Rose A, Pellegrini M, Colla AS. Telomere damage-induced hematopoietic stem cell functional decline is reversible. Nature Conference, Ageing, Health & Rejuvenation 2019, 2019. e-Pub 2019.
25. Thongon N, Jackson C, Lockyer P, Liu J, Santoni A, Rose A, Garcia-Manero G, Colla S. ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage. Blood, 2019. e-Pub 2019.
26. Ganan-Gomez I, Yang H, Ma F, Pellegrini M, Clise-Dwyer K, Garcia-Manero G, Colla AS. Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS. Blood, 2019. e-Pub 2019.
27. Wei Y, Zheng H, Bao N, Kanagal-Shamanna R, Class C, Yang H, PhD, Bravo GM, Ganan-Gomez I, Soltysiak K, Do K, Colla S, Bueso-Ramos CE, Garcia-Manero G. KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Blood, 2019. e-Pub 2019.
28. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos CE, Kanagal-Shamanna R, P Patel K, and Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):465, 2018. e-Pub 2018.
29. Santoni A, Fiorini E, Lay FD, Marchesini M, Ogoti Y, Jackson C, Rose A, Clise-Dwyer K, Ganan-Gomez I, Garcia-Manero G, and Colla S. Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability. Blood 132(Suppl 1):174, 2018. e-Pub 2018.
30. Yang H, Fang Z, Clise-Dwyer K, Ruisaard K, Colla S, Ganan-Gomez I, Montalban-Bravo G, Soltysiak K, Daver NG, Jabbour EJ, Kantarjian HM, and Garcia-Manero G. Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab. Blood 132(Suppl 1):1807, 2018. e-Pub 2018.
31. Ganan-Gomez I, Alfonso A, Yang H, Santoni A, Marchica V, Fiorini E, Montalban-Bravo G, Ogoti Y, Manyam G, Jiang S, Bao N, Jackson C, Rose A, Kanagal-Shamanna R, Bueso-Ramos CE, Cambò B, Giuliani N, Crugnola M, Konopleva MY, Clise-Dwyer K, Garcia-Manero G, and Colla S. Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood 132(Suppl 1):1798, 2018. e-Pub 2018.
32. Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, Kadia TM, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarjian HM, Andreeff M, and Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood 132(Suppl 1):2791, 2018. e-Pub 2018.
33. Montalban Bravo G, Kanagal-Shamanna R, Benton CB, Colla S, Ganan-Gomez I, Sasaki K, Ravandi F, Kadia TM, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Naqvi K, Konopleva MY, Pierce SA, Bueso-Ramos CE, Patel K, Kantarjian HM, and Garcia-Manero G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood 132(Suppl 1):1514, 2018. e-Pub 2018.
34. Fiorini E, Marchesini M, Ogoti Y, Ganan-Gomez I, Colla AS. Persistent telomere dysfunction leads to the expansion of multipotent progenitor cells. Hematopoiesis Keystone Symphosia, 2017. e-Pub 2017.
35. Ganan-Gomez I, Alfonso A, Fiorini E, Colla S. Hematopoietic architecture of MDS reveals two biologically distinct disease subtypes. Irene Ganan-Gomez, Ana Alfonso, Elena Fiorini and Simona Colla. Hematopoiesis Keystone Symphosia, 2017. e-Pub 2017.
36. Marchesini M, Ogoti Y, Fiorini E, D'anca M, Storti P, Nezi L, Samur MK, IreneGañán-Gómez, Fulciniti M, Bohannan ZS, Clise-Dwyer K, Giuliani N, Munshi NC, Orlowski RZ, Garcia-Manero G, DePinho RA, Colla S. ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to DNA damaging agents in 1q21 Multiple Myeloma. Blood, 2017. e-Pub 2017.
37. Ganan-Gomez I, Alfonso A, Yang H, Ogoti Y, Bravo GM, Manero GG, Colla S. Identification of the Specific Hematopoietic Stem Cell Populations Responsible for Failure to Hypomethylating Agents in Myelodysplastic Syndromes. Myelodysplastic Syndromes Symposium, 2017. e-Pub 2017.
38. Wei Y, Garcia-Manero G, Zheng H, Jia Y, Bao N, Jiang S, Khoury JD, Class C, Colla S, and Bueso-Ramos CE. Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice. Blood 130(Suppl 1):50, 2017. e-Pub 2017.
39. Giuliani N, Caramatti C, Roti G, Geata A, Colla S, BonominiMagda Hojden S, La Monica S, Sammarelli G, Lazzaretti M, Craviotto L, Mangoni L, Rizzoli V. Hematologic Malignancies With Extramedullary Spread of Disease. Journal of Clinical Oncology 9(21):1887-1888, 2016. e-Pub 2016. PMID: 12721268.
40. Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 16(Supplement):S67-S73, 2016. e-Pub 2016.
41. Marchesini M, Ogoti Y, Fiorini E, D'anca M, Storti P, Nezi L, Samur MK, Gañán-Gómez I, Fulciniti M, Bohannan ZS, Clise-Dwyer K, Giuliani N, Munshi NC, Orlowski RZ, Garcia-Manero G, DePinho RA, Colla S. ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood 128(22):359, 2016. e-Pub 2016.
42. Pierola AA, Marchesini M, Takahashi K, Gañán-Gómez I, Fiorini E, Ogoti Y, Irles E, Montalban-Bravo G, Sofia S, Dwyer KC, Garcia-Manero G, Colla S. The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. Blood 128(22):958, 2016. e-Pub 2016.
43. Gañán-Gómez I, Alfonso A, Ogoti Y, Yang H, Montalban-Bravo G, Yu AC, Marchesini M, Bueso-Ramos CE, Takahashi K, Clise-Dwyer K, Garcia-Manero G, Colla S. Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. Blood 128(22):4310, 2016. e-Pub 2016.
44. Takahashi K, Wang F, Kantarjian HM, Denaha D, Khann K, Patel KP, Neelapu SS, Gumbs C, Bueso-Ramos CE, DiNardo CD, Colla S, Ravandi F, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futrea A. Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. Blood 128(22):38, 2016. e-Pub 2016.
45. Montalban-Bravo G, Takahashi K, Wang F, Konopleva M, Xingzhi S, Nogueras-Gonzalez GM, Huang X, Pierola AA, Jabbour EJ, Colla S, Borthakur G, Daver N, DiNardo CD, Estrov Z, Kadia TM, Pemmaraju N, Ravandi F, Bueso-Ramos CE, Chamseddine AN, Zhang J, Kantarjian HM, Patel K, Chin L, Futreal A, Garcia-Manero G. Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood 128(22):54, 2016. e-Pub 2016.
46. Wei Y, Zheng H, Jia Y, Bao N, Jiang S, Colla S, Bueso-Ramos CE, Khoury JD, Bohannan ZS, Garcia-Manero G. Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells. Blood 128(22):3149, 2016. e-Pub 2016.
47. Garcia-Manero G, Daver NG, Montalban-Bravo G, Jabbour EJ, DiNardo CD, Kornblau SM, Bose P, Alvarado Y, Ohanian M, Borthakur G, Cortes JE, Naqvi K, Pemmaraju N, Huang X, Nogueras-Gonzalez GM, Bueso-Ramos CE, Gasior Y, Bayer VR, Pierce S, Yang H, Colla S, Kantarjian HM. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood 128(22):344, 2016. e-Pub 2016.
48. Onida F, Iacobelli S, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho TL, Nazha A, Rampal RK, Sanchez ME, Jabbour EJ, Hal Ali N, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Mikkael SA, List AF, Komrokji RS, Tefferi A, Solary E, Padron E. A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood 128(22):4320, 2016. e-Pub 2016.
49. Takahashi K, Wang F, Kantarjian H, Denaha D, Khanna K, Thompson E, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo C, Colla S, Ravandi F, Xingzhi S, Zhang J, Wu X, Samaniego F, Garcia-Manero G, Futreal A. Genetic Mutations that Predict Therapy-Related Blood Cancers. EHA, 2016. e-Pub 2016.
50. Muller FL, Lin Y, Deng P, Satani N, Hammoudi N, Protopopova M, Mohapatra G, Asara JM, Colla S, Wu CC, Marszalek J, Wang A, DePinho RA. NAD biosynthesis as a collateral lethality target in cancer. AACR, 2016. e-Pub 2016.
51. Takahashi K, Wang F, Kantarjian H, Denaha D, Thompson E, Patel K, Neelapu S, Gumbs C, Wang Y, Bohannan Z, DiNardo C, Colla S, Zhang J, Wu X, Manero GG, Futreal A. Clonal origin of therapy-related myeloid neoplasms. AACR, 2016. e-Pub 2016.
52. Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S Takahashi K, Yang H, Estecio MR, Bohannan Z, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcis-Manero G. Expression Of Phosphodiesterase 4 (PDE4) In Myelodysplastic Syndromes (MDS) And Its Impact On Outcome: Result Of A Transcriptome Profiling Using RNA Sequencing From 43 Patients With MDS And Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 15(Supplement 2):S45-S46, 2015. e-Pub 2015.
53. Wei Y, Verma A, Cabrero M, Zheng H, Fang Z, Yu Y, Colla S, Bohannan Z, Boultwood J, Garcia-Manero G. Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood, 2015. e-Pub 2015.
54. Marchesini M, Ogoti Y, Ganan-Gomez I, Wei Y, Bueso-Ramos CE, Garcia-Manero G, DePinho RA, Colla S. Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate. Blood 126(23):1156, 2015. e-Pub 2015.
55. GañánGómez I, Ogoti Y, Marchesini M, Wei Y, Yang H, Jiang S, Bao N, Bueso-Ramos CE, Garcia-Manero G, Colla S. Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. Blood 126(23):2852, 2015. e-Pub 2015.
56. Chamseddine AN, Wei Y, Cabrero M, Ganan Gomez I, Colla S, k T, Yang H, Estecio M, Bohannan ZS, Pierce S, Bueso-Ramos CE, Kantarjian HM, Jabbour E, Garcia-Manero G. PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. Blood 126(23):5227, 2015. e-Pub 2015.
57. Rodriguez Sevilla JJ, Ganan-Gomez I, Colla AS. Myelodysplastic Syndrome Hematopoietic Stem Cells’ Plasticity Drives Venetoclax Therapy Escape. Hematopoiesis. Keystone Symposia, 2014. e-Pub 2014.
58. Marchesini M, Storti P, Ogoti Y, D'Anca M, Nezi L, Wei Y, Yang H, Ong D, Neri A, Giuliani N, Garcia-Manero G, DePinho R, Colla S. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. Blood 124(21):30, 2014. e-Pub 2014.
59. Colla S, Ong D, Ogoti Y, Marchesini M, Mistry N, Clise-Dwyer K, Storti P, Viale A, Wei Y, Giuliani N, Yang H, D'Anca M, Estecio MR, Liang H, Kantarjian HM, Wang AY, Chin L, Bueso-Ramos CE, Garcia-Manero G, DePinho R. A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. Blood 124(21):523, 2014. e-Pub 2014.
60. Wei Y, Cabrero M, Jia Y, Zheng H, Fang Z, Bohannan Z, Chen R, Wang H, Colla S, Wang X, and Garcia-Manero G. Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(21):3241, 2014. e-Pub 2014.
61. Wei Y, Verma A, Cabrero M, Zheng H, Fang Z, Yu Y, Colla S, Bohannan Z, Bowman TV, Boultwood J, Garcia-Manero G. Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood 124(21):4663, 2014. e-Pub 2014.
62. Padron E, Garcia-Manero G, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Lee J, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. Blood 124(21):530, 2014. e-Pub 2014.
63. Wei Y, Jia Y, Zheng H, Yang H, Fang Z, Colla S, Garcia-Manero G. Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). Blood 122(21):1511, 2013. e-Pub 2013.
64. Giuliani N, Novara F, Todoerti K, Zaffaroni N, Villa R, Storti P, Ester Bernardo M, Manferdini C, Gabusi E, Abeltino M, Bolzoni M, Agnelli L, Rocci A, Colla S, Sammarelli G, Rizzoli V, Zuffardi O, Neri A, Lisignoli G. Are the Myeloma Bone Microevironment Cells Tumoral or Not?. Blood 114(11):1816, 2009. e-Pub 2009.
65. Storti P, Donofrio G, Bolzoni M, Colla S, Airoldi I, Sgobba V, Abeltino M, Todoerti K, Agnelli L, Lazzaretti M, Mancini C, Bonomini S, Ribatti D, Pistoia V, Neri A, Rizzoli V, Giuliani N. HOXB7 Is Critically Involved in Multiple Myeloma-Induced Angiogenic Switch. Blood 114(11):125, 2009. e-Pub 2009.
66. Giuliani N, Colla S, Storti P, Sgobba V, Todoerti K, Donofrio G, Bolzoni M, Abeltino M, Lazzaretti M, Bonomini S, Crugnola M, Neri A, Rizzoli V. Oxygen Tension in the Bone Marrow (BM) of Patients with Malignant and Indolent Monoclonal Gammopathy: Role of Hypoxia and Hypoxia-Inducible Factor (HIF)-1 in the Regulation of Gene Expression and Pro-Angiogenic Profiles of CD138+ Cells. Blood 114(11):422, 2009. e-Pub 2009.
67. Bolzoni M, Colla S, Storti P, Donofrio G, Abeltino M, Sgobba V, Bonomini S, Rizzoli V, Giuliani N. Myeloma Cells Inhibit the Non-Canonical Wnt Co-Receptor Ror2 in Human Mesenchymal/Osteoprogenitor Cells: Effect of Wnt5a/Ror2 Pathway Activation On MM-Induced Impairment of the Osteogenic Differentiation Process. Blood 114(11):741, 2009. e-Pub 2009.
68. Colla S, Storti P, Donofrio G, Lazzaretti M, Bonomini S, Lunghi P, Crugnola M, Bolzoni M, Galla L, Ippolito L, Martella E, Sammarelli G, Craviotto L, Caramatti C, Mangoni M, Bonati A, Rizzoli V, Giuliani N. Hypoxia and Hypoxia Inducible Factor (HIF)-1 in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment. Blood 112(11):1687, 2008. e-Pub 2008.
69. Colla S, Giuliani N, Storti P, Lazzaretti M, Todoerti K, Lisignoli G, Agnelli L, Manferdini C, Bonomini S, Galla L, Bolzoni M, Mancini C, Sammarelli G, Mangoni M, Lambertenghi Deliliers G, Neri A, Rizzoli V. HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis. Blood 112(11):2743, 2008. e-Pub 2008.
70. Giuliani N, Colla S, Storti P, Donofrio G, Bolzoni M, Bonomini S, Galla L, Sammarelli G, Mangoni M, Rizzoli V. Activation of Non-Canonical Wnt Pathway in Human Mesenchymal Cells Affects Osteogenic Differentiation: A Potential Target in Multiple Myeloma Microenvironment. Blood 112(11):2742, 2008. e-Pub 2008.
71. Giuliani N, Todoerti K, Lisignoli G, Tagliaferri S, Agnelli L, Morandi F, Colla S, Crugnola M, Magnani M, Caramatti C, Mangoni M, Lambertenghi Deliliers G, Rizzoli V, Neri A. Gene Expression Profiling of Isolated Mesenchymal and Osteoblastic Cells Exhibits a Different Pattern of Expression in Multiple Myeloma Patients as Compared to Healthy Subjects: Potential Relationship with the Presence of Bone Lesions. Blood 110(11):3513, 2007. e-Pub 2007.
72. Giuliani N, Lisignoli G, Tagliaferri S, Lazzaretti M, Morandi F, Colla S, Manferdini C, Tonnarelli B, Rizzoli V. Protein (MIP)-3a/CCL20 and Its Receptor CCR6 Are Overexpressed in the Bone Microenvironment and Involved in Osteoclast Formation in Multiple Myeloma Patients. Blood 110(11):3510, 2007. e-Pub 2007.

Letters to the Editor

1. Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G, Rizzoli V. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 107: 841-2, 2006.
2. Giuliani N, Colla S, Morandi F, Barille-Nion S, Rizzoli V. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Haematologica 90, 2005.
3. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?. Haematologica 89: 611-3, 2004.
4. Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?. Cancer Res 64: 772-3; author reply 774-5, 2004.
5. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, Hojden M, Martella E, Chisesi T, Rizzoli V, Giuliani N. Do human myeloma cells directly produce basic FGF?. Blood 102: 3071-2; author reply 3072-3, 2003.
6. Colla S, Roti G, Rizzoli V, Giuliani N. Angiopoietins expression by human myeloma cells. Haematologica 88: ELT20; author reply ELT21, 2003.

Patents

1. Collateral Gene Inactivation Biomarkers and Targets for Cancer Therapy. Patent Number: 9452182.